Finance entity

UBS

Company UBS

Coverage clusters in markets, which accounts for 3 of those 5, with the remainder spread across 2 other categories. Of the tracked stories, 2 of 5 also mention Jensen Huang, the most common co-covered peer. Sentiment skews less negative than the wider beat, at 20% negative against 29% across all 2361 Finance stories in the same window.

Last mentioned: 2d ago

Entity pulse

Recent coverage · UBS

5 stories
6.6 avg impact
40% positive
20% negative

Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 20 percentage points.

  • 40% positive
  • 40% neutral
  • 20% negative

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about UBS

Coverage clusters in markets, which accounts for 3 of those 5, with the remainder spread across 2 other categories. Of the tracked stories, 2 of 5 also mention Jensen Huang, the most common co-covered peer. Sentiment skews less negative than the wider beat, at 20% negative against 29% across all 2361 Finance stories in the same window. Across a 28-day span, the pace is roughly 1.3 stories per week. At 6.6, the average consequence score sits above the same-window beat average of 6.3. They are less corroborated than the beat average, carrying 2.4 original sources each against 2.6 for the same window. We currently track 5 Finance stories that mention UBS, published between February 26, 2026 and March 25, 2026.

Stories tracked
5
Per week
1.3
Negative
20%
Sources per story
2.4

Computed from the 5 stories linked to this entity, with beat comparisons drawn from all 2361 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering UBS. Shared-story counts are live from our verified record — not editorial picks.

Stories mentioning UBS 5

Financial Regulation Bearish

US Lawmakers Sound Alarm Over Chinese Dominance in Pharmaceutical Supply Chain

The House Select Committee on China has warned that Beijing is executing a strategic 'playbook' to dominate the global pharmaceutical market, mirroring its previous successes in rare earths and electric vehicles. With Chinese medical revenue projected to reach $2.1 trillion by 2030, US officials are weighing the national security risks of a supply chain heavily dependent on Chinese-made active pharmaceutical ingredients.

3 sources

UBS is linked from 5 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.